Results of the Randomized Aldosterone Antagonism in heart failure with Preserved Ejection Fraction trial (RAAM-PEF)

Anita Deswal, Peter Richardson, Biykem Bozkurt, Douglas L. Mann

Research output: Contribution to journalArticlepeer-review

149 Scopus citations

Abstract

Background: Cardiac fibrosis is a major determinant of myocardial stiffness, diastolic dysfunction, and heart failure (HF). By reducing cardiac fibrosis, aldosterone antagonists have the potential to be beneficial in heart failure with preserved ejection fraction (HFpEF). Methods and Results: In a randomized, double-blind, placebo-controlled trial of 44 patients with HFpEF, we examined the effects of eplerenone, an aldosterone antagonist, on changes in 6-minute walk distance (primary end point), diastolic function, and biomarkers of collagen turnover (secondary end points). All patients had a history of hypertension, 61% were diabetic, and 52% had prior HF hospitalization. After 6 months of treatment, similar improvements in 6 minute walk distance were noted in the eplerenone and placebo groups (P = .91). However, compared with placebo, eplerenone was associated with a significant reduction in serum markers of collagen turnover (procollagen type I aminoterminal peptide, P = .009 and carboxy-terminal telopeptide of collagen type I, P = .026) and improvement in echocardiographic measures of diastolic function (E/E', P = .01). Conclusions: Although eplerenone was not associated with an improvement in exercise capacity compared to placebo, it was associated with significant reduction in markers of collagen turnover and improvement in diastolic function. Whether these favorable effects will translate into morbidity and mortality benefit in HFpEF remains to be determined.

Original languageEnglish
Pages (from-to)634-642
Number of pages9
JournalJournal of cardiac failure
Volume17
Issue number8
DOIs
StatePublished - Aug 2011

Keywords

  • Diastolic heart failure
  • diastolic function
  • exercise testing
  • treatment

Fingerprint

Dive into the research topics of 'Results of the Randomized Aldosterone Antagonism in heart failure with Preserved Ejection Fraction trial (RAAM-PEF)'. Together they form a unique fingerprint.

Cite this